Program
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412
Its studies are mostly in Neoplasms, led by Tavotek Biotherapeutics.
Furthest: phase 1, since Sep 14, 20222 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tavotek Biotherapeutics | 22 open or running | phase 1since Sep 14, 2022 | Sep 14, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05548634 · 50 enrolled · United States
- Dec 30, 2024Phase 1 study in NeoplasmsNCT06761651 · 50 planned · China
TargetBeta
“A trispecific antibody targeting hepatocyte growth factor receptor (HGFR; c-Met), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF), ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06761651Neoplasms · China | 1 | Recruiting | Jan 1, 2026 | 50 |
| NCT05548634Neoplasms · United States | 1 | Active, not recruiting | Dec 30, 2025 | 50 |
How it is read
Names in the registry
- “TAVO412”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.